ACHM Association Updates
ACHM ASSOCIATION UPDATES
The ACHM is proud to announce its endorsement of several conferences and meetings. ACHM members may be eligible to receive discounted registration:
- Clinical Symposium on Advances in Skin and Wound Care: The Conference for Prevention and Healing
October 21 – 25, 2009
Grand Hyatt San Antonio and the Henry B. Gonzalez Convention Center
San Antonio, Texas
- Asian Hyperbaric & Diving Medical Association – 5th Annual Meeting: Goa, India
September 25 – 27, 2009
The Bogmallo Beach Resort (www.bogmallobeachresort.com)
For more information, visit our website.
- 2nd Annual Conference on Advancing Wound Healing for Hospitals & Freestanding Clinics
The American College of Hyperbaric Medicine & World Research Group are excited to bring back the 2ndAnnual Conference on Advancing Wound Healing for Hospitals & Freestanding Clinics, taking place January 25-26, 2010, in Orlando, FL.
This year’s conference takes a comprehensive approach on creating and running a profitable wound healing center. We will examine 6 case studies on business and revenue opportunities from therapeutic approaches, as well as 4 case studies on driving profitability and wound center management.
The conference also features two dramatic turn-around case studies, special training on coding and billing strategies, a session on evidence-based medicine and a comprehensive financial workshop on driving P&L.
To register or view our most current agenda, please visit www.worldrg.com/wound or call (800) 647-7600 FREE.
Members of the American College of Hyperbaric Medicine save $400 off the current price! Mention promo code UNK458 to receive the discount.
- WebCME: Providing Online Educational Courses in Hyperbaric Medicine and Wound Care
WebCME offers the only online, fully accredited, 40-hour introductory HBO course. Visit www.WebCME.netor call Kelley Mewissen at (414) 385-2384 for more information.
WebCME is pleased to announce that Wound Care Boot Camp will be available online on October 22nd, 2009. Wound Care Boot Camp is a robust 20 hour introductory course that provides a comprehensive overview of the specialty of wound healing. Lectures are designed to provide students with a broad basic knowledge base and a foundation on which to build clinical algorithms that will allow successful entry into the practice of wound care. Didactic presentations captured in HD video are complimented by actual case studies which serve to illustrate key learning objectives and emphasize clinical material. Wound Care Boot Camp is enriched with round table discussions featuring insights from our expert faculty. This course is ideal for physicians, nurses, and technicians that are new to wound care as well as for those who are already involved in wound healing who want to supplement and build upon their current knowledge.
Topics: Wound Healing Physiology, Assessment and Classification, Pressure Ulcers, Arterial and Venous Insufficiency Ulcers, Diabetic Foot Ulcers, Surgical and Atypical Wounds, Wound Management, Debridement, Infection, Dressings, Nutrition and Advanced Wound Healing Modalities
Faculty: Caroline Fife MD, Patti Smith MD, Dot Weir RN, Larry Lavery DPM, Tom Serena MD, Jeffrey Niezgoda, MD
In partnership with WebCME, the ACHM will offer discounted registration to ACHM members who subscribe to Wound Care Boot Camp.
Last call for exam applications for the October exam in San Antonio, TX. All applications for the October 25, 2009, exam in San Antonio, TX, must be received by September 25, 2009.
The ACHM will administer the MD Hyperbaric Certification Exam in conjunction with the APWCA National Conference in Philadelphia, PA. The exam will take place on Sunday, April 11. Visit our website for additional information or to download the application.
American Hyperbaric Comparative Effectiveness Study Group (ACES Group) recently announced its plans to launch a new Research Registry before the end of this year. This registry is entitled A Prospective, Real World, Multiple Treatment, Multi-Center Clinical Study to Evaluate the Efficacy, Safety and Comparative Effectiveness of Hyperbaric Oxygen in combination with Best Practices in the Treatment of Wagner III Diabetic Foot Ulcers. The Protocol Author and Lead Investigator is Thomas E. Serena MD FACS FACHM, Vice President of the American College of Hyperbaric Medicine. Dr. Serena stated, “The objective of this study is to determine the comparative effectiveness of hyperbaric oxygen in combination with best practices in the promotion of healing and prevention of major amputation in the treatment of diabetic foot ulcers as compared with published diabetic foot ulcer studies for subjects with Type I or Type II diabetes mellitus.” This study will be sponsored by the ACHM and is the first real world trial in wound care and hyperbaric medicine and approximately 250 subjects at multiple sites throughout the United States will be enrolled. Additional information will be provided to ACHM members as we approach the date when recruitment and enrollment begins.
Advanced BioHealing, Inc., the makers of Dermagraft®, a cryopreserved human fibroblast-derived dermal substitute indicated for use in the treatment of chronic full-thickness diabetic foot ulcers (DFUs), recently presented the American College of Hyperbaric Medicine with a $5,000 grant to further research around using hyperbaric oxygen in the treatment of DFUs.
Presenting the check from Dermagraft are Donnie Fischer (far left) and John Malvic (far right). Angela Kujath and Dr. Jeffrey Niezgoda, accepted the grant on behalf of the ACHM.
ATTENTION HYPERBARIC PRACTITIONERS, FACILITIES, WOUND CARE CENTERS & NATIONAL MANAGEMENT COMPANIES.
Post a Job Opportunity or Resume/CV on Our Website
We understand that recruitment in the hyperbaric industry can be difficult. So we’ve created a classified section on our website. Our website receives over 2,000 hits per month, so your listing will be seen by hyperbaric and wound care practitioners throughout the country. Visit our website for more information
We have posted the next two sessions of our educational video series – the Monthly Practice Update. Each month we will feature a different guest who will speak to a specific issue facing hyperbaric practice. This series is broadcast on our website, and is available for ACHM members only. Click here to view the trailer from our first segment.
- Managing a Hyperbaric & Wound Care Practice
Filmed at the Annual Membership Meeting in Philadelphia – Featuring Dr. Jeffrey Niezgoda, ACHM President, and Dr. Thomas Serena, ACHM Vice President
- Risk Management & Insurance Options
Featuring Steven Spector – Managing Director of Risk Management Services, Kolb & Co Financial Advisors
A unique group of specialists from Hyperbaric Medicine, Wound Care, Podiatry, Plastic Surgery and Endovascular Medicine provide information on state-of-the-art advances in Wound Care. These updates are sponsored by various companies with the intent of providing hyperbaric and wound care specialists with updates on the latest advanced modalities, technologies and treatments. This series is broadcast on our website, and is available for ACHM members only.
- Altrazeal – Transforming Powder Dressing
Featuring: Renaat Van den Hoof – CEO, President, Director & John V. St. John, PhD – Vice President, Material Science – Uluru, Inc.
- Topical Oxygen
Featuring Dan Norman – CEO, Pro2Med
Study shows 4% CHG antiseptic is effective against a strain of H1N1 Swine Flu
NORCROSS, Ga., June 24 /PRNewswire/ — Hand washing with a 4% chlorhexidine gluconate (CHG) antiseptic hand washing product is one effective way to stop the spread of the H1N1 Swine Flu Virus.
Hibiclens Antiseptic/Antimicrobial Skin Cleanser and Hibistat Healthcare Personnel Hand Antiseptic Towelettes have been tested and found to be effective against a variation of the A H1N1 Swine Flu Virus, when used according to package instructions. The strain tested was Swine Flu Influenza A H1N1 A/Swine/Iowa/15/3.
The time-kill study, conducted by an independent laboratory showed that Hibiclens(R), a 4% CHG product, reduced the virus by 99.94 percent after 30 second, 60 second, and three minute exposures. Hibistat(R), a 0.5% CHG and 70% isopropyl alcohol formulation, reduced the virus by 99.99 percent after 15 second, 30 second and 60 second exposures. Both Hibiclens and Hibistat were more effective than soap and water which was used as a comparator test product.
“With any type of influenza outbreak, managing the spread of virus is the biggest concern,” said Carolyn Twomey, RN, Global Head of Clinical Services, Molnlycke Health Care. “Influenza viruses usually spread via sneezing and coughing and contaminating one’s hand or hands, and then touching surfaces, shaking hands or other contact behaviors. With any influenza outbreak, good hand hygiene is extremely important. With the current strains of flu virus, this study shows that washing with Hibiclens or using Hibistat Hand Wipes provides additional benefit in preventing transmission.”
Hibiclens is an antimicrobial/antiseptic cleanser that kills germs on contact and bonds with the skin to keep killing microorganisms for up to six hours without leaving a residue. The same cleanser combined with alcohol is available in convenient Hibistat(R) towelettes. Both are available at drug stores and pharmacies in the first aid section. For more information about Hibiclens, Hibistat or CHG, visit www.hibigeebies.com.
About Molnlycke Health Care US, LLC
Molnlycke Health Care US, LLC, consists of two divisions – Surgical and Wound Care. Focusing on prevention of surgically-related infections for both patients and healthcare workers, the Surgical Division (formerly Regent Medical Americas, LLC) encompasses the world’s leading manufacturer and supplier of powder-free surgical gloves (Biogel(R) surgical gloves); the number one supplier (by value) of skin cleanser (Hibiclens(R) and Hibistat(R) antiseptics); and BARRIER(R) protective clothing. A leader in trauma and pain management, the Wound Care Division’s market dynamics are driven by an aging population, higher incidence of pressure ulcers and increased home treatment. SOURCE Molnlycke Health Care
VANCOUVER, BRITISH COLUMBIA–(Marketwire – March 12, 2009) – Ondine Biopharma Corporation (TSX:OBP)(AIM:OBP) (the “Company”) today announced publication of a study demonstrating the first successful decontamination of heavily MRSA-infected wounds in animals. The study was carried out by a team of collaborative researchers at the University College London, UK, and utilized Ondine’s MRSAidTM photodisinfection system which is currently under development.
“The MRSAidTM photodisinfection system builds upon our successful PeriowaveTM technology for treatment of periodontal disease,” stated Dr. Cale Street, Ondine’s Vice President of Research. “The MRSAidTM system was designed to rapidly decolonize the noses of patients carrying the MRSA superbug, reducing the rate of MRSA transmission by a patient to their own surgical incisions as well as to other patients and healthcare workers. In this published work, a team of internationally recognized researchers demonstrated for the first time in vivo photodynamic elimination of the epidemic strain of MRSA that is now unfortunately so common in the UK and elsewhere.”
“This work is important for several reasons,” stated Professor Michael Wilson, Division of Microbial Disease, University College London. “For one, it is a completely novel approach to disinfection of burns and wounds contaminated with the potentially lethal MRSA bacterium. Second, photodynamic disinfection is very unlikely to generate resistance to the treatment that commonly occurs when antibiotics are used. The treatment stays effective time after time. And third, perhaps most important, the treatment is fast. This does not require a course of antibiotics lasting days or weeks. In this study, we were able to reduce MRSA counts by 25-fold in only 30 minutes despite the presence of blood, serum and other wound exudates – with no negative side effects. We look forward to seeing this breakthrough technology deployed in our hospitals, nursing homes and other institutions as a first line of defense against this alarming pathogen.”
About Ondine Biopharma Corporation
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, visit the Company’s website at: www.ondinebiopharma.com.